Skip to content

Axogen AXGN Operating Lease Liabilities

Operating Lease Liabilities at other companies

Baxter International logo
Baxter InternationalBAX
$224M-4.7%
IAR
Integra LifeSciencesIART
$160.12M-0.8%
LeMaitre Vascular logo
LeMaitre VascularLMAT
$17.5M+18.7%

Other financials

Income statement

See full
Revenue$61.5M+26.6%
Gross profit$46.2M+32.2%
Operating income-$2.8M-70.5%
Net income-$19.6M-411%
EPS (diluted)-$0.38-375%

Balance sheet

See full
Cash & equivalents$84.7M+251%
Total debt$20.6M-69.8%
Total equity$244.8M+132%
Total assets$289.5M+47.6%

Cash flow

See full
Operating cash flow$1.6M+112%
CapEx$2.8M+989%
Free cash flow-$1.2M+90.9%

Valuation

See full
Market cap$2.26B+110%
Enterprise value$2.2B+91.4%
P/S9.5×+4.0×

Profitability

See full
Gross margin75%+0.8pp
Operating margin-3.8%
Net margin-13.2%-22.8pp
FCF margin-12.9%-3.8pp

Returns & leverage

See full
Return on equity-18%-70.5pp
Debt / equity0.1×-0.6×
Current ratio7.1×+2.8×

Where this comes from

Reported directly by Axogen in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The official record: Axogen’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axogen's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Axogen's operating lease liabilities?
Axogen (AXGN) reported operating lease liabilities of $18.5M in Q1 2026.
How has Axogen's operating lease liabilities changed year-over-year?
Axogen's operating lease liabilities decreased by 0.6% year-over-year, from $18.61M to $18.5M.
What is the long-term trend for Axogen's operating lease liabilities?
Over 5 years (2020 to 2025), Axogen's operating lease liabilities has grown at a -4.2% compound annual growth rate (CAGR), from $20.86M to $16.84M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.